-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Cullinan Therapeutics, Raises Price Target to $37

Benzinga·05/08/2026 13:44:15
Listen to the news
Wedbush analyst Robert Driscoll maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Outperform and raises the price target from $36 to $37.